This document provides rapid advice on the use of medical masks in communities, at home and at healthcare facilities in areas that have reported outbreaks caused by the 2019 novel coronavirus (2019-nCoV). It is intended for public health and infection prevention and control (IPC) professionals, healthcar...
The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with a novel coronavirus identified in Wuhan, China....
This is the first edition of guidance on infection prevention and control (IPC) strategies for use when infection with a novel coronavirus (2019-nCoV) is suspected. It has been adapted from WHO’s Infection prevention and control during health care for probable or confirmed cases of Middle East respirat...
WHO has developed this interim guidance to meet the need
for recommendations on safe home care for patients with
suspected COVID-19 who present with mild symptoms
a
and
on public health measures related to the management of their
contacts.
This document was adapted from the interim guidance on
Middle Eas...
This updated guideline responds to changes in healthcare delivery and addresses new concerns about transmission of infectious agents to patients and healthcare workers in the United States and infection control. The primary objective of the guideline is to improve the safety of the nation’s healthcare ...
The Guidelines for malaria vector control provide a “one-stop shop” for all countries and partners working to implement effective malaria vector control measures. They cover the 2 core malaria vector control interventions – ITNs and IRS – as well as supplementary interventions, namely chemical an...
The term nanomaterials refers to materials that have at least one dimension (height, width or length) that is smaller than 100 nanometres (10−7 metre), which is about the size of a virus particle. This particular size dimension represents a major characteristic of manufactured nanomaterials (MNMs). The...
This interim guidance document aims to help clinicians with supportive management of patients who have acute respiratory failure and septic shock as a consequence of severe infection. Because other complications have been seen (renal failure, pericarditis, DIC, as above) clinicians should monitor for the...
The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection, as well their use for chemoprophylaxis. This guidance updates and replaces the recommendations published in A...
This revised guidance is published in two parts. Part II documents the procedures followed in developing this guidance, together with a review of evidence and other new information on the pharmacological agents considered....